Accepted: 23 March 2021
First Online: 13 May 2021
Change Date: 17 June 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/S41576-021-00384-2
: A.J.S. and A.G.B. declare no competing interests. M.R.S. receives research funding from ALX Oncology, Astex, Incyte, Takeda and TG Therapeutics; has equity with Karyopharm; and serves as an advisor or consultant to AbbVie, Astex, BMS, Geron, Incyte, Karyopharm, Ryvu, Sierra Oncology, Takeda, Taiho and TG Therapeutics.
Free to read: This content has been made available to all.